Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420212 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
A Phase 3 study of Relapsing Remitting Multiple Sclerosis, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,234
- Enrollment target
- 20
- Study locations
NCT00420212: Completed Phase 3 study of Relapsing Remitting Multiple Sclerosis, sponsored by Biogen.
NCT00420212 is a Phase 3 study of Relapsing Remitting Multiple Sclerosis that has completed, run by Biogen. The registered enrollment target is 1,234 participants, above the 153-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (707% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00420212, a Phase 3 study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,234 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse. The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.
Primary Outcome
A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BG00012
Study Locations (20)
Massachusetts
- Research Site - Brighton
- Research Site - Hopedale
- Research Site - Lexington
- Research Site - Springfield
- Research Site - Worcester
Arizona
- Research Site - Gilbert
- Research Site - Phoenix
Illinois
- Research Site - Evanston
- Research Site - Palos Heights
Indiana
- Research Site - Fort Wayne
- Research Site - Indianapolis
California
- Research Site - San Francisco
Connecticut
- Research Site - New Haven
District of Columbia
- Research Site - Washington D.C.
Florida
- Research Site - Vero Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,234 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
What the finished NCT00420212 record still lists
NCT00420212 is an interventional study that assigns participants to a tested intervention. Its 1,234 participants enrollment target places it among the larger protocols in the corpus, above the 153-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (707% higher).
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00420212 names 20 study sites across 13 states, led by Massachusetts, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT00420212 about?
NCT00420212 is a clinical study titled "Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis". To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get wors...
What is the current status of trial NCT00420212?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,234 participants. The study started on 2007-01. Estimated completion is 2011-02.
What conditions does trial NCT00420212 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
What interventions are being tested in trial NCT00420212?
The interventions under investigation include: Placebo (DRUG), BG00012 (DRUG).
Who is sponsoring clinical trial NCT00420212?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00420212 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00420212's enrollment target sits among peer trials
1,234 1st of 25 higher than 25 of 25 other Relapsing Remitting Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
COMPLETED · Phase 3
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT06368245 · 1,244 participants
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia